[1] Maitra A, McKenna RW, Weinberg AG, et al. Precursor B-cell lymphoblastic lymphoma. A study of nine cases lacking blood and bone marrow involvement and review of the literature[J].Am J Clin Pathol, 2001, 115(6):868-875. [2] Burkhardt B, Zimmermann M, Oschlies I, et al. The impact of age and gender on biology, clinical features and treatment outcome of non-Hodgkin lymphoma in childhood and adolescence[J]. Br J Haematol, 2005, 131(1):39-49. [3] Ducassou S, Ferlay C, Bergeron C, et al. Clinical presentation, evolution, and prognosis of precursor B-cell lymphoblastic lymphoma in trials LMT96, EORTC 58881, and EORTC 58951[J]. Br J Haematol, 2011, 152(4):441-451. [4] Thomas DA, O'Brien S, Cortes J, et al. Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma[J]. Blood, 2004, 104(6):1624-1630. [5] Kantarjian HM, O'Brien S, Smith TL, et al. Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia[J]. J Clin Oncol, 2000, 18(3):547-561. [6] Sun X, Zhen Z, Zhu J, et al. Outcomes of modified NHL-BFM-90 protocol for children and adolescents with lymphoblastic lymphoma[J]. Zhonghua Xueyexue Zazhi, 2014, 35(12):1083-1089. [7] Villa-Morales M, Cobos MA, González-Gugel E, et al. FAS system deregulation in T-cell lymphoblastic lymphoma[J]. Cell Death Dis, 2014, 5:e1110. [8] Alexander W. A peer-reviewed journal for formulary management[J].Am Soc Hematol, 2016, 41(2):120. [9] Ko RH, Ji L, Barnette P, et al. Outcome of patients treated for relapsed or refractory acute lymphoblastic leukemia:a therapeutic advances in childhood leukemia consortium study[J]. J Clin Oncol, 2010, 28(4):648-654. [10] Brown PA, Shah B, Fathi A, et al. NCCN guidelines insights:Acute lymphoblastic leukemia, version[J]. J Natl Compr Canc Netw, 2017, 15(9):1091-1102. [11] 徐舟, 潘慈, 陈静,等. 70例儿童淋巴母细胞淋巴瘤远期疗效评估[J]. 中华血液学杂志, 2013, 34(12):1044-1049. [12] 孙晓非, 甄子俊, 夏奕,等. B淋巴母细胞淋巴瘤的临床特点和采用改良BFM-90方案治疗的结果[J]. 中华血液学杂志, 2006, 27(10):649-652. [13] 亓凯, 黎阳, 方建培,等. 儿童中高危T淋巴母细胞淋巴瘤与急性淋巴细胞白血病30例临床分析[J]. 中国实用儿科杂志, 2015,30(5):377-382. [14] 金玲, 张蕊, 黄爽,等. 儿童淋巴母细胞淋巴瘤的临床特点和预后分析[J]. 中华肿瘤杂志, 2012, 34(2):138-142. [15] Welinder E, Mansson R, Mercer EM, et al. The transcription factors E2A and HEB act in concert to induce the expression of FOXO1 in the common lymphoid progenitor[J]. Proc Natl Acad Sci USA, 2011, 108(42):17402-17407. [16] Pang SH, Minnich M, Gangatirkar P, et al. PU.1 cooperates with IRF4 and IRF8 to suppress pre-B-cell leukemia[J]. Leukemia, 2016, 30(6):1375-1387. [17] Lilljebjörn H, Fioretos T. New oncogenic subtypes in pediatric B-cell precursor acute lymphoblastic leukemia[J]. Blood, 2017, 130(12):1395-1401. [18] Mullighan CG. New strategies in acute lymphoblastic leukemia:translating advances in genomics into clinical practice[J]. Clin Cancer Res, 2011, 17(3):396-400. [19] Harrison C. Cytogenetics of paediatric and adolescent acute lymphoblastic leukaemia[J]. Br J Haematol, 2009, 144(2):147-156. [20] Zhou Y, You MJ, Young KH, et al. Advances in the molecular pathobiology of B-lymphoblastic leukemia[J]. Hum Pathol, 2012, 43(9):1347-1362. [21] Dias A, Kenderian SJ, Westin GF, et al. Novel therapeutic strategies in acute lymphoblastic leukemia[J]. Curr Hematol Malig Rep, 2016, 11(4):253-264. [22] 林东京,傅迪,彭梅,等.美罗华联合CHOP方案与依托泊苷联合CHOP方案治疗弥漫大B细胞淋巴瘤研究[J].中国实用内科杂志,2016,36(1):60-63. [23] 王莉,黄德鸿,肖春燕,等.单形性嗜上皮性肠道T细胞淋巴瘤3例报道与文献复习[J].解放军医学杂志,2018,43(1):45-50. |